The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia
Sign Up to like & getrecommendations! Published in 2018 at "Neuropharmacology"
DOI: 10.1016/j.neuropharm.2018.09.005
Abstract: ABSTRACT Dopamine (DA)‐replacement therapy utilizing l‐DOPA is the gold standard symptomatic treatment for Parkinson's disease (PD). A critical complication of this therapy is the development of l‐DOPA‐induced dyskinesia (LID). The endogenous opioid peptides, including enkephalins… read more here.
Keywords: mmp 2200; mmp; dopa induced; receptor ... See more keywords